July 21, 2017 2 min read

As preventable causes continue to take too many lives in some of the most vulnerable parts of the world, international organizations have teamed up to launch innovative efforts to combat this problem.  Malaria in pregnancy is a health risk for both mother and fetus, and determining the precise drug regimen for pregnancy in malarious areas is an ongoing challenge.

One of these initiatives, known as “Transforming IPT for Optimal Pregnancy” (TIPTOP), aims to give pregnant women in sub-Saharan Africa access to a preventive therapy for malaria known as “intermittent preventive treatment in pregnancy” (IPTp).  IPTp is well documented as a method to prevent malaria in pregnancy, specifically using three doses of sulphadoxine-pyrimethamine (SP) to PREVENT malaria during the course of pregnancy.

This five-year TIPTOP project will increase IPTp coverage through local distribution of quality-assured medicine as well as expand antenatal care in the Democratic Republic of Congo, Madagascar, Mozambique, and Nigeria. TIPTOP plans to help local community health workers increase IPTp delivery and make sure that anyone who needs the medicine will have access, which includes reaching out to 400,000 pregnant women and their babies. Data and evidence from this approach will also go toward helping policymakers update their IPTp policies.  It is important to note that the WHO currently does recommend that pregnant women in areas of moderate to high transmission of malaria receive IPT, which is detailed in WHO Guidelines. 

Nearly half a million people each year died from malaria in 2015, with approximately 90% of all these deaths occurring in Africa (WHO, 2016). Due to reduced immune response, pregnant women are less able to fight off malaria infections and are three times more likely to suffer more serious complications that can lead to death for both mother and baby. Malarial infection during pregnancy can lead to miscarriage, premature birth, low birth weight, congenital infection, and/or death (CDC, 2013).

Unitaid and Jhpiego, an international nonprofit health organization affiliated with the Johns Hopkins University, signed an agreement in early May of this year in support of TIPTOP. Unitaid is investing USD$50 million in the project, while Jhpiego is collaborating with the Barcelona Institute for Global Health, WHO, and Medicines for Malaria Venture to ensure that the desired results and goals are reached. Furthermore, these partnerships reflect ongoing international commitment to the United Nations Development Programme’s Sustainable Development Goal 3: to accelerate maternal and newborn mortality reduction in Sub-Saharan Africa.

 

by Vivian Shih, Maternova

blog by Vivian Shih

Leave a comment

Comments will be approved before showing up.


Also in The Maternova Blog

What's new in menstrual health management: an interview with the Founder of Asan
What's new in menstrual health management: an interview with the Founder of Asan

April 28, 2024 2 min read

The Asan cup is a patented menstrual cup with a unique removal ring, which makes it the easiest cup to insert and take out. The bell-shaped design ensures that the cup sits comfortably, and the red colour of the cup prevents it from staining over time. 
Read More
Benefits of intravenous iron to treat anemia in pregnancy
Benefits of intravenous iron to treat anemia in pregnancy

March 19, 2024 5 min read

Read More
A Point of Care Bilirubinometer Using Blood: BiliDx
A Point of Care Bilirubinometer Using Blood: BiliDx

January 16, 2024 2 min read

The BiliDx is a novel system for diagnosing jaundice.  The device uniquely meets the Target Product Profile (TPP) developed as part of the NEST 360 initiative in that it allows blood-based testing at the bedside.   This initiative is part of an emerging global consensus in the Every Newborn Action Plan that countries need functional WHO level-2 inpatient units to care for "small and sick newborns." 
Read More